The results of this report are summarized in Figure 6, illustrating the differences in the RET-fusion partner genes involving KIAA1217. This study provided experimental evidence supporting the use of vandetanib and promoting KIAA1217-RET as a novel target for personalized cancer therapy. The gene discussed is KIAA1217; the disease is cancer.